Belmont, CA-based Ventus Medical has rounded up an impressive $40 million in Series D financing. Ventus plans to use to money to commercialize Provent Sleep Apnea Therapy, the company's prescription device for sleep apnea. In addition to the financing, Ventus announced that it has named a new president and CEO. Peter Wyles joins Ventus from Bayer HealthCare, where he led the consumer, pharmaceutical and medical device businesses in Germany, Japan, Canada and the U.S.
"Peter brings an impressive record of start-up expansion, consumer and prescription product marketing and executive leadership," says Jeff Nugent, Chairman of Ventus, in a statement. "His proven track record in general management and global marketing expertise will add tremendous value as we continue to focus on expanding our position in the sleep disordered breathing market."
- read the release for more
PLUS: TriVascular announced the close of $60 million in funding, comprised of a Series C equity financing and growth capital venture debt. New investor Pinnacle Ventures led the round. Proceeds from the financing will be used to launch the company's Ovation Abdominal Stent Graft System in Europe, fund clinical research activity, and fuel next generation product development. TriVascular release
ALSO: Molecular diagnostics company Metamark Genetics has completed a $22 million Series B financing, which it will use to expand R&D and clinical testing infrastructure, in addition to establishing its commercial organization. Metamark Genetics
AND: Accuri Cytometers has rounded up $6 million in Series E financing. The new funds will primarily be used to complete the development and regulatory activities needed for Accuri to market the Accuri C6 Flow Cytometer System for in vitro diagnostic applications. Release